GOSSAMER BIO, INC. Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price
GOSSAMER BIO, INC. (GOSS) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price of $0.91 per share for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice · last filed 2026-08-13
- GOSSAMER BIO, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2026-03-31 was $0.94, a 16.81% decline year-over-year.
- GOSSAMER BIO, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2025-03-31 was $1.13, a 14.14% increase year-over-year.
- GOSSAMER BIO, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2024-03-31 was $0.99, a 18.85% decline year-over-year.
- GOSSAMER BIO, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2023-03-31 was $1.22, a 89.71% decline year-over-year.
- GOSSAMER BIO, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2025 was $1.23, a 28.13% increase from fiscal 2024.
- GOSSAMER BIO, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2024 was $0.96, a 17.24% decline from fiscal 2023.
- GOSSAMER BIO, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2023 was $1.16, a 82.81% decline from fiscal 2022.
- GOSSAMER BIO, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2022 was $6.75, a 31.26% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $0.91 10-Q · filed 2026-08-13 | ||||
| 2026-03-31 | $0.94 10-Q · filed 2026-05-15 | ||||
| 2025-12-31 | $1.23 10-K · filed 2026-03-17 | ||||
| 2025-09-30 | $1.16 10-Q · filed 2025-11-05 | ||||
| 2025-06-30 | $1.14 10-Q · filed 2025-08-05 | ||||
| 2025-03-31 | $1.13 10-Q · filed 2025-05-15 | ||||
| 2024-12-31 | $0.96 10-K · filed 2026-03-17 | ||||
| 2024-09-30 | $0.96 10-Q · filed 2024-11-07 | ||||
| 2024-06-30 | $0.96 10-Q · filed 2024-08-12 | ||||
| 2024-03-31 | $0.99 10-Q · filed 2024-05-07 | ||||
| 2023-12-31 | $1.16 10-K · filed 2026-03-17 | ||||
| 2023-09-30 | $1.30 10-Q · filed 2023-11-09 | ||||
| 2023-06-30 | $1.30 10-Q · filed 2023-08-08 | ||||
| 2023-05-05 | $1.36 10-K · filed 2026-03-17 | ||||
| 2023-03-31 | $1.22 10-Q · filed 2023-05-09 | ||||
| 2022-12-31 | $6.75 10-K · filed 2025-03-13 | ||||
| 2022-09-30 | $11.50 10-Q · filed 2022-11-03 | ||||
| 2022-06-30 | $11.53 10-Q · filed 2022-08-09 | ||||
| 2022-03-31 | $11.86 10-Q · filed 2022-05-10 | ||||
| 2021-12-31 | $9.82 10-K · filed 2024-03-05 | ||||
| 2021-09-30 | $9.67 10-Q · filed 2021-11-08 | ||||
| 2021-06-30 | $9.70 10-Q · filed 2021-08-09 | ||||
| 2021-03-31 | $9.82 10-Q · filed 2021-05-06 | ||||
| 2020-12-31 | $13.78 10-K · filed 2023-03-17 | ||||
| 2020-09-30 | $14.02 10-Q · filed 2020-11-10 | ||||
| 2020-06-30 | $14.30 10-Q · filed 2020-08-11 | ||||
| 2020-03-31 | $14.55 10-Q · filed 2020-05-12 | ||||
| 2019-12-31 | $20.11 10-K · filed 2022-03-03 | ||||
| 2019-09-30 | $20.79 10-Q · filed 2019-11-12 | ||||
| 2019-06-30 | $21.13 10-Q · filed 2019-08-08 | ||||
| 2019-03-31 | $21.74 10-Q · filed 2019-05-14 | ||||
| 2018-12-31 | $7.49 10-K · filed 2021-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 |